Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.51 |
| ▸ | ESRRA | P11474 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31750473 | 1.00 | ALDH1A1 (0.53) | ALDH1A1HPGDNPSR1VCAM1ESRRA | |
| SCHEMBL28965687 | 0.90 | ALDH1A1 (0.48) | ALDH1A1HPGDNPSR1VCAM1ESRRA | |
| SCHEMBL26654534 | 0.84 | MAPT (0.47) | ALDH1A1HPGDLMNASMN1; SMN2MAPT | |
| SCHEMBL2239592 | 0.81 | PDGFRB (0.51) | ALDH1A1HPGDNPSR1VCAM1LMNA | |
| SCHEMBL26767338 | 0.81 | MAPT (0.47) | ALDH1A1HPGDNPSR1VCAM1LMNA | |
| SCHEMBL7566531 | 0.80 | ALDH1A1 (0.65) | ALDH1A1HPGDNPSR1VCAM1LMNA | |
| SCHEMBL30445111 | 0.80 | ALDH1A1 (0.65) | ALDH1A1HPGDNPSR1VCAM1LMNA | |
| SCHEMBL26768026 | 0.79 | CHEK1 (0.42) | ALDH1A1ESRRALMNASMN1; SMN2MAPT | |
| SCHEMBL31750422 | 0.78 | VCAM1 (0.41) | ALDH1A1HPGDNPSR1VCAM1SMN1; SMN2 | |
| SCHEMBL26767710 | 0.78 | PDGFRB (0.39) | ALDH1A1HPGDNPSR1VCAM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365558-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2023-11-16 | — | — | US | disclosed |
| US-20090306062-A1 | 2,5-Disubstituted Piperidines | NOVARTIS AG (CH) | 2009-12-10 | — | — | US | disclosed |
| WO-2009106599-A2 | SUBSTITUTED PIPERIDINES AS THERAPEUTIC COMPOUNDS | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | disclosed |
| EP-2044059-A1 | 2,5-DISUBSTITUTED PIPERIDINES | Speedel Experimenta AG (CH) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007141318-A1 | 2,5-DISUBSTITUTED PIPERIDINES | SPEEDEL EXPERIMENTA AG (CH) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365558-A1 | TETRAHYDROISOQUINOLINE DERIVATIVE AND USE THEREOF | CYP3A7, UGT2B7, SFPQ | ALDH1A1 1495/4885HPGD 1266/4885NPSR1 2636/4885 |
| US-20090306062-A1 | 2,5-Disubstituted Piperidines | REN, AGTR1, AGTR2 | ALDH1A1 466/4885HPGD 790/4885NPSR1 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.